Medically reviewed by Jay N. Yepuri, MD Metabolic dysfunction-associated steatohepatitis (MASH) is an advanced form of ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH) is a disease that occurs when steatosis (a buildup of fat) in the liver causes liver inflammation and damage.

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

One-third of children with metabolic dysfunction-associated steatotic liver disease receiving standard of care showed improvement after 2 years.

Researchers identify the Asah1 gene as a promising target for novel therapies to treat nonalcoholic fatty liver disease ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Understanding the molecular mechanisms of these transporters provides valuable insights into liver disease pathophysiology and offers potential therapeutic targets for managing NAFLD, NASH ...

Following the third quarter 2024 completion of enrollment in IMPACT, our Phase 2b biopsy-based trial of pemvidutide in NASH, our top line ... pemvidutide's direct action on the liver, together ...